Member Info for Rocka

The report states the company has £1.04 million in cash as of 31 March 2026.The Math: A revenue of £2.13 million against a micro-cap biotech structure means their operational costs (lab equipment, scientists, overheads) burn through cash rapidly.The Reality: £1.04 million is a very small safety net for a biotech firm. Within the next 6 to 12 months, they will almost certainly run low on cash again. When that happens, they will be forced to launch another share placing to raise funds, diluting the shares you own and forcing the stock price down.2. The Revenue Growth is an "Accounting Illusion"The RNS boasts a jump in gross margin to 50%, but look at the footnote very carefully: *Underlying gross margin excludes the IP transfer agreement with Finn Therapeutics.The Trick: The revenue includes a £250k intellectual property sale to Finn Therapeutics.The Hidden Risk: The text explicitly notes that this £250k was "recognised" (counted on paper), but "payment to be received in FY2027 on completion of a fundraise by Finn Therapeutics."What this means: Fusion Antibodies has recorded revenue for money they haven't actually received yet. If Finn Therapeutics fails to raise money this year, that £250k could vanish. Stripping that out, their true underlying margin is much lower, and their real organic commercial growth is incredibly slow.

The fact that £40,000 blocks of shares can be sold instantly does not mean there is safe consumer demand; it means specialized institutional market makers are stepping in to absorb those shares at a steep discount, often dropping the price for everyone else.The active community on the London South East (LSE) share chat for Fusion Antibodies directly addresses these "40k sells". Believing that easy selling equates to safety is a dangerous misconception about how penny stocks function.

This is for you mhater

An institutional or high-net-worth investor buying £500,000 worth of shares at 12p does not mean your individual position is safe, and it is a dangerous reason to stay in a trade.

Relying on an institution's entry price as your safety net is a structural trap. You must understand why their financial reality is completely different from yours, why it makes holding a massive risk for your remaining savings, and what to do next.

While it is true that Fusion Antibodies raised £1.4 million in January 2026 at an issue price of 13p, you must look closely at their cash burn rate. Independent financial assessments from platforms like Simply Wall St show that the company's free cash flow leaves them with a very limited cash runway.The dilution cycle: Unprofitable biotech companies survive by burning through cash and then creating new shares to raise more. Every time they issue new shares (like they did in January), your personal shares become worth less of the company.Why it drops: The stock didn't slide to 11.80p by accident. The market is actively pricing in the fact that the company is unprofitable and will likely need to dilute shareholders yet again in the future to keep the lights on.

Not me saying this but chatgpt!

The "Sucker Stock" Reality: Financial analysts currently categorize FAB as a underperforming, highly speculative stock. Over the last year, it has constantly fluctuated wildly between roughly 6p and 21p, showing zero stable growth.

Next placing will most probably be lower than 13p unless Adrian comes up with something very quickly

That means nothing, i’ve seen this countless times where placees invest and the sp keeps dropping, very common on AIM so that isnt a very good selling point!

The Board remains cautiously optimistic for FY2027. The combination of a stronger and more diversified pipeline, an increasing engagement with larger pharmaceutical customers, deployment of cutting-edge technologies and progress in proprietary platform validation is key to the Company's success.

As well as this, the Company also has support from non-dilutive funding sources which provides a solid foundation for future growth. However, the Board remains mindful of ongoing macroeconomic uncertainty and the inherent variability of project-based revenues.

Outlook.. no mention of nci/optimal. You would think they would put this in the outlook as its what we are all waiting for. To me it sounds like they haven't managed to come to an agreement, now he is talking about european and America pharma’s but we have no idea how much this is generating for the company. The drop is to be expected!!!

Update the market? Really Chris? If he had any positive news he would have updated us, thats my point, there is nothing to update about, he initially thought people will be rushing to get optimal but that’s clearly not happened.

This is just dead tbh. Everyone making excuses but 7 months on from optimal launch and we are at 12p!!

Looks like Adrian has nothing up his sleeve. No significant contracts, nothing on optimal. You must admit its not looking good

11.5/12p crazy

Was expecting an RNS. If Adrian knows investors are P off and does nothing, this means he has no news , nothing to announce. If the tech is good , trust me they will be signing contracts and big pharma’s will be chasing them.

Big £18k sell

Oh yes keep reporting when im tellig the truth, bid now 11.50, want to buy more Chris? As it drops ? 11, 10 then 9 etc, im the only one who has th guts to post what you all think but wont admit

Why the hell did i invest in the pos is beyond me !!

Another day goes by and Adrian has delivered F all.

In the meantime, so has dropped once again… the fall continues..

Mm fiver? Add five zero’s to that 5!

Rp you’re dreaming, todays rns and couples with the sp falling recently and the selling suggests i am right. Employee wants to get what they can before it ultimately drops to 4,3,2 then 1p

This is actually a negative. Employee probably knows this is going nowhere and expects this to tank and has probably heard something which is why they want to get out as they probably think it ‘ll drop below 4p in the future